Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation Full Text
International Journal of Women's Health, 04/13/2012
Kinov P et al. – Delayed–release risedronate is a promising, new, effective, and convenient alternative to current bisphosphonate treatments. It appears to allow better patient adherence to antiresorptive treatment.
- Bisphosphonates are the most widely prescribed treatment for postmenopausal osteoporosis, secondary osteoporosis, and male osteoporosis.
- Notwithstanding their high effectiveness and favorable safety profile, the adherence to bisphosphonate treatment remains low.
- Different treatment strategies aim to improve the clinical effectiveness of bisphosphonate therapy.
- This review paper assesses the clinical utility of oral intermittent risedronate in the treatment of postmenopausal osteoporosis.
- The new delayed–release risedronate formulation is a safer and easy to use alternative to other risedronate therapy.
- Oral risedronate, a potent nitrogen–containing bisphosphonate, has been extensively studied using daily regimens.
- A new intermittent (weekly) dosing regimen confirmed its clinical effectiveness in relation to vertebral and nonvertebral fracture prevention.
- The absence of significant differences in the incidence of adverse effects confirmed the favorable tolerability of the weekly dosage.
- In efforts to improve patient adherence to treatment, an innovative, delayed–release formulation of risedronate, which ensures adequate bioavailability of the active compound when taken with food, was introduced.
- The once–weekly delayed–release formulation of risedronate proved to be noninferior to the daily dosage of risedronate in terms of bone mineral density and markers of bone turnover.
- In addition, the incidence of new morphometric vertebral fractures was comparable in both treatment regimens.
- The new delayed–release formulation of risedronate showed a favorable safety profile.